Mylan says US FDA's generic user fee not discriminatory despite foreign inspection cost differential

This article was originally published in SRA

16 Jan 2012
News

Anju Ghangurde @ScripAnjuG anju.ghangurde@informa.com

Executive Summary

US generic manufacturer Mylan believes that any claims of bias against foreign manufacturers within the US Food and Drug Administration's proposed generic drug user fee plan are "misplaced" and that the programme offers parity for all industry participants¹. The US firm, seen as a "driving force" behind the proposal, also sees the programme securing American competitiveness and jobs.

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS116618

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS116618

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

Mylan says US FDA's generic user fee not discriminatory despite foreign inspection cost differential

News

Executive Summary

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert